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Introduction
Hepatic stellate cells, which reside in the space of Disse in
close contact with both sinusoidal endothelial cells and
hepatocytes, play multiple roles in the pathophysiology of
the liver [1]. Quiescent stellate cells represent a principal
retinol-storing phenotype and metabolize a small amount
of basement membrane-forming substrata such as lam-
inine and type IV collagen. When liver injury occurs, they
undergo transformation into myofibroblasts eliciting
active proliferation in response to platelet-derived growth
factor-BB (PDGF-BB) and insulin-like growth factor-1
(IGF-1), increased extracellular matrix (ECM) production,
increased contractility that is accompanied by the expres-
sion of smooth muscle α-actin and the production of
endothelin-1 (ET-1), secretion of transforming growth
factor-beta (TGF-beta) and monocyte chemotactic pro-
tein-1 (MCP-1), retinoid loss, and exhibiting active apop-
tosis. Stellate cell activation is initiated by oxidative stress
of lipid hydroperoxide and reactive aldehyde generated
and released by damaged hepatocytes, by paracrine stim-
ulation of PDGF-BB, IGF-1 and TGF-beta derived from
activated Kupffer cells, endothelial cells, platelets and
infiltrating leukocytes, and by early ECM changes includ-
ing the production of a splice variant of cellular fibronec-
tin (EIIIA isoform) [2-5]. Transcriptional activation by a
zinc finger gene KLF6, which is induced at the very early
stage of liver injury, AP-1 and CCAAT/enhancer binding
protein (C/EBP) enhances gene expression regulating
ECM accumulation [6]. Activated stellate cells are highly
responsive to PDGF-BB and IGF-1 through the induction
of receptors for individual growth factors, resulting in the
activation of intracellular signal cascade including phos-
phorylation of tyrosine residues in each growth factor
receptor molecule, mitogen activated protein kinase
(MAPK), phosphatidil inositol 3-kinase (PI3-K), leading
to DNA synthesis and proliferation [7,8]. TGF-beta is a key
regulatory molecule for ECM metabolism and functions
as an autocrine and a paracrine mediator. The impact of
TGF-beta1 on liver fibrosis has been well documented in
a TGF-beta1 knockout mouse model [9], in the remarka-
ble attenuation of the development of liver fibrosis by
using soluble type II TGF-beta receptor [10], and in aden-
oviral delivery of dominant-negative TGF-beta receptor
[11]. Role of Smad cascade in TGF-beta signaling has been
well characterized. Increased contractility after activation,
in particular induced by ET-1, causes constriction of sinu-
soids, leading to a persistent disturbance of intrahepatic
microcirculation and portal hypertension [12,13]. Thus,
analysis of the molecular mechanism underlying stellate
cell activation is assumed to be essential for the develop-
ment of effective therapy against liver fibrosis.
Proteomics
The genome project will finish by 2003 and will reveal the
sequence of all genes encoded in the genome for a total of
3,000 Mb [14,15]. This urges to develop genomics
research permitting the analysis of more than 10,000
genes at one time by using gene chip technology. Such a
newly developing approach has accelerated the discovery
of genetic or common disease genes. Although calculated
number of genes encoded in the genome is though to be
about 40,000, 5,000 – 6,000 proteins are estimated to be
generated in each type of cell and hence only a part of the
genes in the genome are expressed in a cell- and tissue-
specific manner. Therefore, analysis of cellular proteins,
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especially the change in their expression level and their
post-transcriptional modification, is definitely required.
The proteome (protein + genome), or proteomics, refers
to the total protein profile of a given cell or tissue type.
Advantage of proteomics is referred to more accurate pic-
ture of the genome's plan by measuring proteins directly
because i) there exists difference between the rates of deg-
radation of individual mRNAs and proteins and ii) pro-
teins are received post-translational modification, e.g.
phosphorylation and glycation. Disadvantage of pro-
teomics may be i) requirement of "skilled staff" for 2-
dimensional PAGE, ii) low sensitivity, iii) failure of the
detection of some of the most interesting proteins, such as
membrane receptor and low-abundance signal molecules,
and iv) unavailability of amplification method for pro-
teins like PCR. Recent advancement of technology related
to proteomics will overcome these disadvantages in the
near future.
Proteomics involves the following experimental steps.
First, proteins are separated by two-dimensional polyacr-
ylamide gel electrophoresis (2-D PAGE) [16]. This tech-
nique combines isoelectric focusing (IEF) in the first
dimension with sodium dodecyl sulfate (SDS) PAGE in
the second dimension, and it is capable of separating sev-
eral thousands of proteins on a single 2-D gel. Second,
individual proteins are identified and characterized by
mass spectrometric techniques such as matrix-assisted
laser desorption ionization (MALDI) or electrospray ioni-
zation (ESI) mass spectrometry [17,18]. Advances in these
techniques of protein analysis using mass spectrometry
(MS) has made it possible to increase the sensitivity of
analysis (less than 100 fmol of proteins can be analyzed)
and shorten the time for analysis (only 30 min is required
for the partial sequencing of one protein spot). Moreover,
the tandem mass (MS/MS) method directly represents the
amino acid sequence of the protein spot analyzed without
any pre-purification by such methods as high-perform-
ance liquid chromatography, resulting in the determina-
tion of the protein by reference to the database.
In practice, samples were prepared from quiescent or acti-
vated stellate cells, intact or fibrotic liver, and conditioned
medium. They were dissolved in a lysis buffer composed
of 7 M urea, 2 M thiourea, 4% (w/v) CHAPS, 2% (v/v)
ampholine, and 1% DTT and applied overnight to Immo-
bilone DryStrip (pH 4–7, Pharmacia). After IEF, two-
dimensional SDS-PAGE was performed in 9–18% acryla-
mide gradient gels. Proteins were visualized by silver
staining. The protein spots of interest were excised from
the 2-D gels and digested overnight at 37°C in a buffer
containing trypsin. After a brief purification, they were
applied to Q-TOF mass spectrometer. The MS mode was
used to scan samples for detectable peptides. Subse-
quently, the MS/MS mode was used to fragment individ-
ual peptides, and from the resulting MS/MS spectra the
amino acid sequence was deduced for each peptide.
Finally, the proteins were identified after searching the
obtained amino acid sequences against the SwissProt and
GenBank database.
A total of 308 protein spots from stellate cells have been
successfully identified. These include 225 protein spots
derived from stellate cell lysate and 83 spots of secreted
proteins. Among the identified proteins were Cu2+/Zn2+
superoxide dismutase, plasminogen activator inhibitor 1,
ubiquitin, vimentin, and several heat-shock proteins. Sev-
eral proteins whose expression levels were up- or down-
regulated in the course of stellate cell activation were iden-
tified. These include actin-binding proteins, such as calcy-
clin, calgizzarin and F-actin capping protein, proteases,
such as cathepsin D, gamma enolase, and serine protease,
and neural cell adhesion molecule (N-CAM). Interesting
was that we detected the difference in protein level
between "in vitro" activated stellate cells and "in vivo" acti-
vated stellate cells. For instance, FK506 binding protein 6,
heat shock protein 90-beta and oestronectin were
detected in "in vitro", but not "in vivo" activated stellate
cells. In addition, protein level of coffilin, destrin and pro-
teasome delta chain was much higher in "in vitro" acti-
vated stellate cells than in "in vivo" ones [19]. Thus, we
should keep in mind that the culture model does not
always precisely reflect the cellular metabolism at the
physiological situation.
Discovery of STAP
In the course of the proteomics approach, we successfully
isolated a novel protein dabbed STAP after stellate cell
activation-associated protein and cloned its cDNA (stap)
[20]. Rat STAP protein with pI 6 and molecular mass of 21
kDa was found to be present in stellate cells at their quies-
cent stage and to be markedly up-regulated during the
course of their activation in both in vivo and in culture.
Induction of STAP protein coincided with the expression
of another activation markers of the cells, such as PDGFR-
beta, smooth muscle α-actin and N-CAM. STAP expres-
sion was dramatically augmented in a fibrotic liver model
of rats induced by thioacetamide, indicating a profound
role of STAP in the rat hepatic pathophysiology including
fibrosis. Further information obtained by immunohisto-
chemistry of whole body organs of rats revealed that STAP
would be a promising marker for vitamin A-storing cells
in the extra-hepatic organs; STAP was detected in pancre-
atic stellate cells and renal mesangial cells as well as mes-
enchymal cells in the submucosal layer of the stomach
and the intestines where the presence of vitamin A-storing
cells was confirmed previously.Comparative Hepatology 2004, 3 http://www.comparative-hepatology.com/content/3/S1/S3
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Homologous sequences to rat stap cDNA were found in
human genome DNA database. By using the data, we
designed primers and performed RT-PCR to amplify
human stap cDNA by using cDNA derived from mRNA of
human cultured stellate cells as a template. As a result, a
658 bp cDNA was obtained. The deduced amino acid
sequence of the cDNA had 94 and 97% identity to rat stap
and unknown mouse full-length cDNA (accession
number AK019410), respectively. Thus, we concluded
this clone as human stap. Two histidine residues were
found in human STAP as in rat STAP at 81 and 113 from
the N-terminus that might be expected to be involved in
heme binding sites from the similarity with amino acid
sequences of hemoglobin and myoglobin. BLAST search
identified that human stap  locates on chromosome 17
between sialyltransferase and hypothetical protein
FLJ22341 and is composed of 4 exons, spanning 111140
to 102176 in RP11-666A8 clone [21].
STAP mRNA was expressed in human various organs and
Hep G2 cells. Immunohistochemistry revealed that STAP-
positive cells in the liver were stellate cells. STAP expres-
sion was not augmented around inflammatory necrotic
areas where myofibroblasts were accumulated. As rat
STAP, recombinant human STAP exhibited the character-
istics of a heme protein with the activity of myeloperoxi-
dase and lipid hydroperoxide dehydrogenase, but not
glutathione peroxidase. These results indicate that human
STAP is a novel human heme protein with peroxidase
activity and can be used as a marker for stellate cells in
human liver tissues.
Very recently, another laboratories reported homologous
cDNAs to STAP from mouse and human and named them
as cytoglobin and histoglobin, respectively. In accordance
with our results, both cytoglobin and histoglobin are
hemoprotein and are expressed in multiple organs. Taken
together, STAP consists of a new family of globin other
than hemoglobin and myoglobin.
Overexpression of STAP in NIH 3T3 cells revealed that
STAP may regulate cell growth via reducing p21 expres-
sion. This experiment further showed that STAP may up-
regulate mRNA expression of type I collagen and TGF-
beta, indicating a profound role of STAP in fibrotic gene
expression.
Although molecular function of STAP is beginning to be
uncovered, the data obtained to date indicate the pro-
found role of STAP in fibrotic potential and vitamin A
metabolism of stellate cells in the liver as well as in the
extra-hepatic organs.
Thus, the proteomics approach is highly useful to analyze
protein/gene expression of stellate cells in response to
their activation in in vitro and in vivo. Such a global cata-
logue of protein expression will greatly increase under-
standing of stellate cell biology and the molecular
mechanism of liver fibrosis.
Therapeutic Strategy for Preventing Liver 
Fibrosis
Increasing numbers of studies have shown a variety of
therapeutic approaches for liver fibrosis based on the
molecular inhibition of stellate cell activation.
Among them, interferon (IFN) has a clinical potential to
treat liver fibrosis by eliminating HCV virus from patients
[22]. IFN-Gamma inhibits stellate cell activation, collagen
transcription through directly acting onto IFN-responsive
element, a proximal element within the human alpha 2(I)
collagen (COL1A2) promoter, and TGF-beta/Smad signal-
ing through STAT pathway [23,24].
In animal models, liver fibrosis could be inhibited by a
soluble receptor consisting of a chimeric IgG at the extra-
cellular portion of the TGF-beta type II receptor and by the
adenovirus-mediated local expression of a dominant-neg-
ative type II TGF-beta receptor (AdCATb-TR) [10,11].
We reported that N-acetyl-L-cysteine triggers the degrada-
tion of PDGF receptor beta mediated by cathepsin B. N-
acetyl-L-cysteine inhibits PDGF signaling, PDGF-depend-
ent DNA synthesis, and in addition, affected the expres-
sion of TGF-beta receptor type II. N-acetyl-L-cysteine
dramatically attenuated liver fibrosis in rat models [25].
HGF gene therapy is promising for the treatment of liver
fibrosis. Ueki et al. reported that repeated transfections of
the human HGF gene into skeletal muscle suppressed the
increase of TGF-beta 1, inhibited fibrogenesis and hepato-
cyte apoptosis, and resolved completely fibrosis in the cir-
rhotic liver [26].
Thiazolidinediones are clinically used as antidiabetic
agents, which are ligands for peroxisome proliferator-acti-
vated receptor gamma (PPARgamma). Thiazolidinedi-
ones and the other PPARgamma ligands, such as 15-J-
PGJ2, have been reported to inhibit proliferation and
smooth muscle α-actin expression in cultured stellate cells
[27-29]. A more recent report demonstrated that adminis-
tration of thiazolidinediones reduced ECM deposition
and stellate cell activation in both toxic and cholestatic
model of liver fibrosis in rats [30].
References
1. Friedman SL: The cellular basis of hepatic fibrosis. N Engl J Med
1993, 328:1828-1835.
2. Gressner AM, Bachem MG: Molecular mechanism of liver fibro-
sis-a homage to the role of activated fat-storing cells. Digestion
1995, 56:335-346.Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
Comparative Hepatology 2004, 3 http://www.comparative-hepatology.com/content/3/S1/S3
Page 4 of 4
(page number not for citation purposes)
3. Olaso E, Friedman SL: Molecular regulation of hepatic fibrogen-
esis. J Hepatol 1998, 29:836-847.
4. Kawada N: The hepatic perisinusoidal stellate cell. Histol His-
topathol 1997, 12:1069-1080.
5. Okuyama H, Shimahara Y, Kawada N: The hepatic stellate cells in
the post-genomic ear. Histol Histopathol 2002, 17:487-495.
6. Kim Y, Ratziu V, Choi SG, Lalazar A, Theiss G, Dang Q, Kim SJ, Fried-
man SL: Transcriptional activation of transforming growth
factor beta1 and its receptors by the Kruppel-like factor Zf9/
core promoter-binding protein and Sp1. Potential mecha-
nisms for autocrine fibrogenesis in response to injury. J Biol
Chem 1998, 273:33750-33758.
7. Marra F, Gentilini A, Pinzani M, Choudhury GG, Parola M, Herbst H,
Dianzani MU, Laffi G, Abboud HE, Gentilini P: Phosphatidylinositol
3-kinase is required for platelet-derived growth factor's
actions on hepatic stellate cells.  Gastroenterology 1997,
112:1297-1306.
8. Kawada N, Ikeda K, Seki S, Kuroki T: Expression of cyclins D1, D2
and E correlates with proliferation of rat stellate cells in cul-
ture. J Hepatol 1999, 30:1057-1064.
9. Hellerbrand C, Stefanovic B, Giordano F, Burchardt ER, Brenner DA:
The role of TGFbeta1 in initiating hepatic stellate cell activa-
tion in vivo. J Hepatol 1999, 30:77-87.
10. George J, Roulot D, Koteliansky VE, Bissell DM: In vivo inhibition of
rat stellate cell activation by soluble transforming growth
factor beta type II receptor: A potential new therapy for
hepatic fibrosis. Proc Natl Acad Sci 1999, 96:12719-12724.
11. Qi Z, Atsuchi N, Ooshima A, Takeshita A, Ueno H: Blockade of
type beta transforming growth factor signaling prevents
liver fibrosis and dysfunction in the rat. Proc Natl Acad Sci 1999,
96:2345-2349.
12. Kawada N, Tran-Thi TA, Klein H, Decker K: The contraction of
hepatic stellate (Ito) cells stimulated with vasoactive sub-
stances. Possible involvement of endothelin 1 and nitric
oxide in the regulation of the sinusoidal tonus. Eur J Biochem
1993, 213:815-823.
13. Rockey DC, Weisiger RA: Endothelin induced contractility of
stellate cells from normal and cirrhotic rat liver: implica-
tions for regulation of portal pressure and resistance. Hepatol-
ogy 1996, 24:233-240.
14. Kahn P: From genome to proteome: looking at a cell's pro-
teins. Science 1995, 270:369-370.
15. Anderson NL, Anderson NG: Proteome and proteomics: new
technologies, new concepts, and new words.  Electrophoresis
1998, 19:1853-1861.
16. O'Farrell PH: High resolution two-dimensional electrophore-
sis of proteins. J Biol Chem 1975, 250:4007-4021.
17. Roepstorff P: Mass spectrometry on protein studies from
genome to function. Curr Opin Biotechnol 1997, 8:6-13.
18. Yates JR: Mass spectrometry and the age of the proteome. J
Mass Spectrom 1998, 33:1-19.
19. Kristensen DB, Kawada N, Imamura K, Miyamoto Y, Tateno C, Seki
S, Kuroki T, Yoshizato K: Proteome analysis of rat hepatic stel-
late cells. Hepatology 2000, 32:268-277.
20. Kawada N, Kristensen DB, Asahina K, Nakatani K, Minamiyama Y,
Seki S, Yoshizato K: Characterization of a stellate cell activa-
tion-associated protein (STAP) with peroxidase activity
found in rat hepatic stellate cells.  J Biol Chem 2001,
276:25318-25323.
21. Asahina K, Kawada N, Kristensen DB, Nakatani K, Seki S, Shiokawa
M, Tateno C, Obara M, Yoshizato K: Characterization of Human
stellate cell activation-associated protein (STAP) and its
expression in human liver.  Biochim Biophys Acta 2002,
1577:471-475.
22. Shiratori Y, Imazeki F, Moriyama M, Yano M, Arakawa Y, Yokosuka
O, Kuroki T, Nishiguchi S, Sata M, Yamada G, Fujiyama S, Yoshida H,
Omata M: Histologic improvement of fibrosis in patients with
hepatitis C who have sustained response to interferon ther-
apy. Ann Intern Med 2000, 132:517-524.
23. Higashi K, Kouba DJ, Song YJ, Uitto J, Mauviel A: A proximal ele-
ment within the human alpha 2(I) collagen (COL1A2) pro-
moter, distinct from the tumor necrosis factor-alpha
response element, mediates transcriptional repression by
interferon-gamma. Matrix Biol 1998, 16:447-456.
24. Ulloa L, Doody J, Massague J: Inhibition of transforming growth
factor-beta/SMAD signalling by the interferon-gamma/
STAT pathway. Nature 1999, 397:710-713.
25. Okuyama H, Shimahara Y, Kawada N, Seki S, Kristensen DB,
Yoshizato K, Uyama N, Yamaoka Y: Regulation of cell growth by
redox-mediated extracellular proteolysis of platelet-derived
growth factor receptor beta. J Biol Chem 2001, 276:28274-28280.
26. Ueki T, Kaneda Y, Tsutsui H, Nakanishi K, Sawa Y, Morishita R, Mat-
sumoto K, Nakamura T, Takahashi H, Okamoto E, Fujimoto J: Hepa-
tocyte growth factor gene therapy of liver cirrhosis in rats.
Nat Med 1999, 5:226-230.
27. Miyahara T, Schrum L, Rippe R, Xiong S, Yee HF Jr, Motomura K, Ana-
nia FA, Willson TM, Tsukamoto H: proliferator-activated recep-
tors and hepatic stellate cell activation.  J Biol Chem 2000,
275:35715-35722.
28. Marra F, Efsen E, Romanelli RG, Caligiuri A, Pastacaldi S, Batignani G,
Bonacchi A, Caporale R, Laffi G, Pinzani M, Gentilini P: Ligands of
peroxisome proliferator-activated receptor gamma modu-
late profibrogenic and proinflammatory actions in hepatic
stellate cells. Gastroenterology 2000, 119:466-478.
29. Li L, Tao J, Davaille J, Feral C, Mallat A, Rieusset J, Vidal H, Lotersztajn
S: 15-deoxy-Delta 12,14-prostaglandin J2 induces apoptosis
of human hepatic myofibroblasts. A pathway involving oxi-
dative stress independently of peroxisome-proliferator-acti-
vated receptors. J Biol Chem 2001, 276:38152-38158.
30. Galli A, Crabb DW, Ceni E, Salzano R, Mello T, G Svegliati-Baroni,
Ridolfi F, Trozzi L, Surrenti C, Casini A: Antidiabetic thiazolidine-
diones inhibit collagen synthesis and hepatic stellate cell acti-
vation in vivo and in vitro. Gastroenterology 2002, 122:1924-1940.